Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.

Beyer-Westendorf, Jan; Lensing, Anthonie W A; Arya, Roopen; Bounameaux, Henri; Cohen, Alexander T; Wells, Philip S; Middeldorp, Saskia; Verhamme, Peter; Hughes, Rodney; Kucher, Nils; Pap, Akos F; Trajanovic, Mila; Prins, Martin H; Prandoni, Paolo; Weitz, Jeffrey I (2017). Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis research, 149, pp. 29-37. Elsevier 10.1016/j.thromres.2016.11.014

[img] Text
Beyer_WestendorfJ_ChoosingWisely_ThrombResearch_2017.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (715kB) | Request a copy

BACKGROUND The results of the EINSTEIN-DVT/PE and AMPLIFY trials, which compared rivaroxaban and apixaban with conventional anticoagulation therapy for acute venous thromboembolism (VTE), respectively, are often compared. However, the trials differed in duration of therapy (3-12 and 6months, respectively) and in patient selection (few exclusion criteria and more stringent exclusion criteria, respectively). METHODS To determine the effect of these methodological differences on outcomes, the patients enrolled in EINSTEIN-DVT/PE were divided into 2 cohorts; the 5253 patients that matched the exclusion criteria for AMPLIFY and were treated for at least 6months (cohort 1) and the 2368 patients who would have been ineligible for AMPLIFY (cohort 2). RESULTS Compared with patients in cohort 2, those in cohort 1 were older and more often male and there were more with unprovoked VTE, prior VTE, cancer and known thrombophilia. In cohort 1, rivaroxaban would have significantly reduced recurrent VTE (relative risk [RR], 0.64; 95% confidence interval [CI], 0.43-0.95) and major bleeding (RR, 0.50; 95% CI, 0.30-0.82) compared with conventional therapy, whereas the two treatments would have had similar effects on recurrent VTE (RR, 1.08; 95% CI, 0.65-1.79) and major bleeding (RR, 1.03; 95% CI, 0.48-2.18) in cohort 2. CONCLUSIONS This analysis illustrates the influence of patient selection and treatments duration on outcome results and highlights the limitations of cross-trial comparisons.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology

UniBE Contributor:

Kucher, Nils

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0049-3848

Publisher:

Elsevier

Language:

English

Submitter:

Isabel Lorenz

Date Deposited:

13 Dec 2019 10:26

Last Modified:

13 Dec 2019 10:26

Publisher DOI:

10.1016/j.thromres.2016.11.014

PubMed ID:

27886530

Uncontrolled Keywords:

anticoagulation apixaban rivaroxaban venous thromboembolism

BORIS DOI:

10.7892/boris.136657

URI:

https://boris.unibe.ch/id/eprint/136657

Actions (login required)

Edit item Edit item
Provide Feedback